Here are four observations:
1. Biologics’ popularity among spine surgeons will drive the market, along with the minimally invasive nature of the procedure and a growing geriatric population.
2. Currently, North America holds the largest market share, with Europe coming in second, due to advanced technologies and high per capita income.
3. The Asian-Pacific market is set to grow at a high rate because of an increasing population, better medical coverage and growing demand in India and China.
4. Key market players include Alphatec Spine, DePuy Synthes, Medtronic, Stryker, Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.
More articles on devices:
Conventus Orthopaedics names new CEO — 4 things to know
Mazor Robotics, Stryker, K2M & more: 19 device company key notes
Vertebral compression fracture devices market to reach $1.1M by 2022: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
